Brief: Ix Biopharma Says Co & FDA Reached Agreement On Key Aspects Of A Phase 3 Clinical Trial
10/12/2019 15:14
Dec 10 (Reuters) - IX Biopharma Ltd IXBI.SI :
* IX BIOPHARMA- CO & FDA REACHED AGREEMENT ON KEY ASPECTS OF
PHASE
3 CLINICAL TRIAL PROGRAM TO SUPPORT APPROVAL OF WAFERMINE FOR
INDICATION OF PAIN
Source text for Eikon: ID:nSNZ2jCq3
Further company coverage: IXBI.SI
((Reuters.Briefs@thomsonreuters.com;))
Recent news on IX Biopharma
See all newsBrief: Ix Biopharma Confirms Orion Not Yet Obtained Licence From Nevada State Board Of Pharmacy
Brief: Ix Biopharma Says U.S. Govt Opens Emergency Pathway, Clears Path For Wafermine Application For EUA
Brief: IX Biopharma Says Co Will Undertake An Internal Restructuring Of Its Consumer Business
Brief: IX Biopharma To Issue 1 MLN New Shares To Anson Properties At S$0.4215 Per Share
Brief: IX Biopharma Says US Government Awards US$41 MLN Contract To Fund Development Of Wafermine